OR30-06 Assessment of Dulaglutide Safety in Older Patient Populations in Rewind

Background: Dulaglutide (DU) was superior to placebo (PL) in reducing the incidence of Major Adverse Cardiovascular Events in the Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND Study) broad patient population. The safety of DU treatment is also of interest to health car...

Descripción completa

Detalles Bibliográficos
Autores principales: Konig, Manige, Gerstein, Hertzel C, Lakshmanan, Mark C, Xavier, Denis, Atisso, Charles, Allen, Sheryl, Cushman, William C, Leiter, Lawrence A, Raubenheimer, Peter J, Franek, Edward M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Diabetes Mellitus and Glucose Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207332/
http://dx.doi.org/10.1210/jendso/bvaa046.071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207332/
http://dx.doi.org/10.1210/jendso/bvaa046.071

Ejemplares similares